The New ADHD Medications of 2024-2026: Qelbree, Azstarys, Onyda XR, and the Modern Pharmacopeia

How to Read This Review

ADHD pharmacology has organized for decades around three molecular families: methylphenidate-class stimulants, amphetamine-class stimulants, and non-stimulants (atomoxetine and the alpha-2 agonists guanfacine and clonidine). The recent approvals do not reshuffle this taxonomy — they extend it. Knowing which molecule is inside a new branded product, and what its delivery system actually does pharmacokinetically, is what distinguishes a real prescribing decision from a marketing-driven one. For background on the underlying pharmacology, see the companion review ADHD Pharmacology and the Natural Course of Illness.

Why Most "New" ADHD Medications Aren't Really New

A new ADHD product reaching the U.S. market does not necessarily mean a new molecular entity. From approximately 2008 to 2024, the FDA approved more than a dozen new ADHD products. Only a handful contained a new chemical compound. The rest were reformulations — new salt forms, beads, dissolution profiles, and vehicle systems delivering molecules in use for ADHD since the 1950s through 1990s.

The distinction matters because the active compound determines pharmacology, side-effect profile, abuse potential, and mechanism. The delivery system determines duration, onset, smoothness, and whether the medication can be given to a child who cannot swallow a capsule. Reformulations can be genuinely useful — Jornay PM's evening dosing solves the morning-effectiveness problem that has plagued methylphenidate prescribing for decades — but they should be evaluated as delivery innovations, not pharmacological ones.

The post-2020 reformulation landscape includes Adhansia XR, Adzenys XR-ODT and Adzenys ER, Dyanavel XR, Mydayis, Jornay PM, Quillivant XR, Quillichew ER, and Cotempla XR-ODT. Each has a plausible niche. None is pharmacologically novel. The three approvals worth treating as genuinely new are Qelbree, Azstarys, and Onyda XR — and even Onyda XR is technically an existing molecule in a new delivery vehicle. I include it because the liquid extended-release formulation enables a clinical use case that did not previously exist in the labeled space.

Qelbree (Viloxazine, SPN-812): The First New Non-Stimulant in Over a Decade

FDA approval: April 2, 2021 for pediatric ADHD (ages 6-17); April 29, 2022 for adult ADHD. Developed by Supernus Pharmaceuticals as SPN-812.

Class: Non-stimulant. Schedule: not controlled.

Viloxazine has an unusual development history. The molecule was originally marketed in Europe as an antidepressant in the 1970s-1980s (trade name Vivalan), withdrawn in the 2000s for commercial — not safety — reasons. Supernus reformulated it as an extended-release capsule with a different dose range and pharmacokinetic profile and developed it specifically for ADHD, producing the first novel non-stimulant FDA-approved for ADHD in over a decade (the previous being atomoxetine in 2002).

Mechanism of Action

Viloxazine is most accurately described as a serotonin-norepinephrine modulating agent. The exact mechanism is multi-receptor:

• Norepinephrine reuptake inhibition — viloxazine inhibits the norepinephrine transporter, similar in basic mechanism to atomoxetine. This is generally considered the dominant ADHD-relevant mechanism.
• 5-HT2C receptor agonism — viloxazine has agonist activity at the serotonin 5-HT2C receptor, which is implicated in prefrontal cortical control of dopamine signaling.
• 5-HT2B receptor antagonism — viloxazine antagonizes the 5-HT2B receptor.
• Minimal serotonin reuptake activity at clinical doses — distinguishing viloxazine from classical SSRIs and SNRIs.

This multi-receptor profile is mechanistically distinct from atomoxetine, which is a relatively pure norepinephrine reuptake inhibitor. Whether the serotonergic activity contributes meaningfully to ADHD efficacy or is primarily responsible for adverse effects is unresolved.

Efficacy Evidence

The pediatric approval was supported by a development program of four phase 3 trials enrolling more than 1,000 children and adolescents ages 6-17. In each trial, participants were randomized to viloxazine at 100, 200, 400, or 600 mg daily versus placebo for 6-8 weeks. Across studies, viloxazine produced statistically significant reductions in the ADHD Rating Scale-5 (ADHD-RS-5) total score relative to placebo, with effect sizes in the small-to-moderate range typical of non-stimulant ADHD treatments. Notably, separation from placebo was apparent as early as week 1 in some studies — somewhat faster than the 2-6 week onset typically described for atomoxetine.

The adult approval was based on a phase 3 randomized double-blind placebo-controlled trial published in CNS Drugs in 2022. Adult patients on viloxazine extended-release showed greater reduction in the Adult ADHD Investigator Symptom Rating Scale (AISRS) total score (-15.5 ± 0.91) compared to placebo (-11.7 ± 0.90), p = 0.0040. The effect size in adults was clinically meaningful but again in the modest range typical of non-stimulant approaches in adult ADHD.

Practical Tradeoffs

The most common pediatric adverse effects are somnolence, decreased appetite, headache, fatigue, nausea, and irritability. Viloxazine carries a boxed warning for suicidal ideation and behavior in pediatric patients — a class-level warning shared with other monoaminergic agents in younger patients, requiring monitoring but not contraindication.

The argument for Qelbree over atomoxetine: somewhat faster onset, potentially better tolerability for patients with prior GI or sexual side effects on atomoxetine, and no obligatory titration to weight-based target (atomoxetine must reach 1.2 mg/kg/day in pediatric patients). The argument against: atomoxetine is generic and far cheaper, with no head-to-head trial establishing Qelbree's superiority. In my prescribing, Qelbree has a clear role after atomoxetine failure or intolerance; for first-line non-stimulant choice in cost-sensitive patients, generic atomoxetine remains the rational starting point.

Azstarys (Serdexmethylphenidate + Dexmethylphenidate, KP415): The Prodrug Approach

FDA approval: March 2, 2021. Developed by KemPharm (now Zevra Therapeutics) and Corium.

Class: Stimulant (methylphenidate family). Schedule II (combined product).

Azstarys is a capsule containing two distinct components:

• Serdexmethylphenidate (SDX) — a prodrug of dexmethylphenidate, comprising approximately 70% of the active stimulant load. SDX is itself pharmacologically inert; it must be enzymatically cleaved in the gastrointestinal tract to release dexmethylphenidate (d-MPH), the active stimulant.
• Dexmethylphenidate (d-MPH) — immediate-release, comprising approximately 30% of the active stimulant load. This provides the initial pharmacological effect within the first 30-60 minutes after dosing.

Pharmacokinetic Rationale

The design combines the rapid onset of an immediate-release stimulant (d-MPH) with the smooth, extended duration of a prodrug-based release (gradual GI conversion of SDX). Plasma d-MPH concentrations rise within an hour of dosing and persist approximately 13 hours, with a flatter overall curve than traditional extended-release methylphenidate. Whether this is clinically meaningfully smoother than Concerta or Focalin XR is hard to demonstrate — head-to-head comparative effectiveness trials are scarce.

Scheduling and Abuse Liability

Why is Azstarys Schedule II if SDX is a prodrug? Two reasons: the co-formulated product contains immediate-release d-MPH, which is Schedule II; and the DEA placed SDX itself into Schedule IV in 2021 recognizing its reduced abuse potential, but the combined branded product is dispensed at the higher schedule. The prodrug architecture would matter more if SDX were ever developed as a standalone Schedule IV product, which has been discussed but not commercialized to date.

Practical Prescribing

Azstarys is dosed once daily in the morning, available in three strengths (26.1/5.2, 39.2/7.8, 52.3/10.4 mg SDX/d-MPH), approved for ages 6 and older. It is most useful when a patient has tolerated dexmethylphenidate-family medications (Focalin, Focalin XR) and is seeking a smoother release profile. The decision to use Azstarys over Focalin XR is typically driven by individual response and tolerability rather than class superiority.

Onyda XR (Clonidine Hydrochloride ER Liquid): The First Liquid Alpha-2 Agonist

FDA approval: May 24, 2024. Developed by Tris Pharma.

Class: Alpha-2 adrenergic agonist (non-stimulant). Schedule: not controlled.

Onyda XR is clonidine hydrochloride formulated as an extended-release oral suspension, 0.1 mg/mL, dosed once daily at bedtime. It is the first and only liquid extended-release non-stimulant approved for ADHD in the United States. It is approved as monotherapy or as adjunctive therapy to CNS stimulants in patients aged 6 years and older.

Why a Liquid Alpha-2 Agonist Matters

A substantial minority of children either cannot swallow pills, refuse to, or have unreliable tablet adherence. Until Onyda XR, the only alpha-2 agonists for ADHD were Intuniv (guanfacine ER tablet, now generic) and Kapvay (clonidine ER tablet, now generic). For a young child who cannot swallow tablets and for whom stimulants are not the preferred class, the prescriber's options were limited. Onyda XR fills that gap.

Mechanism

Clonidine is a central alpha-2 adrenergic receptor agonist. By stimulating presynaptic alpha-2 receptors in the locus coeruleus and prefrontal cortex, it reduces norepinephrine release, modulating arousal and improving prefrontal cognitive control. The mechanism is distinct from stimulants (dopamine and norepinephrine reuptake) and from atomoxetine and viloxazine (norepinephrine transporter). Clonidine is sedating — the property that makes it useful for ADHD-related sleep disruption.

Onyda XR vs. Existing Generic Options

From a prescribing standpoint, Onyda XR competes with two generic alpha-2 agonist tablets:

• Generic guanfacine ER (formerly Intuniv) — once-daily morning dosing typical, mild-to-moderate sedation, somewhat slower onset, generally better tolerated for daytime cognitive effects
• Generic clonidine ER (formerly Kapvay) — typically twice-daily dosing or once at bedtime, more pronounced sedation, more useful for sleep dysregulation and impulsivity than for daytime attention specifically

The branded Onyda XR is the same molecule as generic clonidine ER, in a liquid extended-release vehicle, with labeled once-daily bedtime dosing. The cost difference is substantial — generic clonidine ER costs are typically a small fraction of branded Onyda XR. In a patient who can swallow tablets, generic clonidine ER or guanfacine ER are nearly always the rational starting choices.

Where Onyda XR earns its prescription: a young child or a child with documented inability to swallow tablets, and an indication for a non-stimulant alpha-2 agonist. In that specific situation, Onyda XR solves a real clinical problem that no other approved product solves as cleanly.

The Reformulation Landscape: Same Molecule, Different Delivery

The non-novel-molecule approvals of the past decade have been delivery innovations on top of methylphenidate or amphetamine. Here is the practical framework I use when matching a patient to one of these products.

The substantive point: every product in this table can be matched, pharmacologically, to a generic counterpart. Whether the reformulation justifies its branded price tag depends on whether the delivery system solves a specific problem for the specific patient. For school-aged children with poor morning functioning, Jornay PM is genuinely different from morning-dosed extended-release methylphenidate. For pill-averse children, the liquid and ODT options solve a real adherence problem. For most adults, the older generic extended-release products perform very similarly to the newer branded versions.

For a deeper comparison of two of the most commonly confused methylphenidate products, see Concerta vs. Ritalin. For the amphetamine side, see Adderall vs. Vyvanse.

The Vyvanse Generic Transition: The Most Important Change of the Era

On August 25, 2023, the FDA approved 15 manufacturers' generic versions of lisdexamfetamine (Vyvanse) capsules, with chewable tablet generics following. This was the first generic approval since the molecule's original 2007 FDA approval.

From a prescribing standpoint, this matters more than any new branded approval since 2020. Lisdexamfetamine is one of the two most widely prescribed ADHD medications in the U.S. (with mixed amphetamine salts being the other), and price compression on a high-volume drug changes prescribing economics broadly. Pre-generic Vyvanse cash prices averaged approximately $400-$556 for a 30-day supply of 30 mg capsules; post-generic retail prices fell to approximately $300-$439 in the first year, with continued downward pressure as additional manufacturers entered. FDA estimates suggest over $1 billion in U.S. healthcare savings in the first 18 months.

Therapeutic Equivalence

The FDA-approved generics are designated A-rated, meaning therapeutically equivalent to brand-name Vyvanse. They contain the same active ingredient (lisdexamfetamine dimesylate) in the same strengths and dosage forms. The differences are in inactive ingredients (fillers, dyes) and in capsule appearance. Reported clinical experience has been generally consistent with brand-name product; isolated patient complaints about generic efficacy do appear, as they do with any generic transition in psychiatry, but population-level evidence supports equivalence.

For prescribers, the generic transition has substantially expanded the patient population for whom lisdexamfetamine is a reasonable first-line stimulant. Where pre-2023 cost considerations frequently forced use of Adderall or generic methylphenidate as initial trials, the post-2023 economic landscape allows generic lisdexamfetamine to be a credible first-line option in cost-sensitive patients — though tier placement on individual insurance formularies still varies.

The Non-Stimulant Landscape in 2026

The non-stimulant armamentarium in 2026 has four well-established and one investigational entrant:

When to Use Non-Stimulants First

The standard guidance, and my practice, is to use stimulants as first-line in most patients with ADHD — they have the largest effect sizes (Cohen's d in the 0.7-1.0 range) compared to non-stimulants (0.3-0.6 range), faster onset, and the longest treatment-effect evidence base. Non-stimulants come first in defined clinical situations:

• Active substance use disorder or strong family history of stimulant misuse where prescriber and patient prefer to avoid controlled substance
• Patient or parent preference against controlled substance prescription
• Significant tic disorder where stimulant exacerbation is a concern (clinical evidence is mixed but caution remains standard)
• Anxiety disorder that worsened or appeared on stimulant trials (atomoxetine and alpha-2 agonists are typically anxiolytic or neutral)
• Cardiovascular or arrhythmia risk that makes the prescriber prefer to avoid stimulant exposure — for the population-level evidence on stimulant cardiovascular safety, see ADHD Medications and Cardiovascular Safety
• Sleep disruption as a prominent feature, where clonidine ER's sedating profile is therapeutically useful

For the broader stimulant-versus-non-stimulant decision framework, see Stimulants vs. Non-Stimulants and the more detailed blog discussion Stimulant vs. Non-Stimulant: Choosing Between ADHD Medication Classes. For the bupropion question that comes up in this discussion, see Wellbutrin (Bupropion) for ADHD.

Pediatric-Specific Considerations

Pill-Swallowing as a Prescribing Constraint

In typical pediatric practice, 25-40% of children under age 10 cannot reliably swallow tablets. This is a practical adherence problem, not a developmental concern. The current pill-alternative menu is broad: Dyanavel XR (amphetamine suspension and chewable), Quillivant XR (methylphenidate suspension), Quillichew ER (methylphenidate chewable), Methylin oral solution, Adzenys XR-ODT (amphetamine ODT), Cotempla XR-ODT (methylphenidate ODT), Onyda XR (clonidine ER liquid). Many capsules can be opened and sprinkled. Pill-swallowing as a skill can also be taught in 3-5 behavioral sessions.

School Dosing and Morning Coverage

Extended-release products solved most of the midday school-dose problem; Jornay PM solved the inverse problem — needing the medication active first thing in the morning before the child wakes, without requiring the family to wake the child for an early dose.

Growth Monitoring and Long-Term Outcomes

Stimulants are associated with modest reductions in expected growth velocity — approximately 1-2 cm in height and 1-3 kg in weight over multi-year treatment. The effect attenuates over time and most children reach their genetically expected adult height. Routine height-and-weight monitoring is the clinical response, not avoidance. The role of drug holidays for growth recovery is debated; the data support a modest summer effect but do not support drug holidays for efficacy or tolerance reasons. For the broader long-term outcomes evidence on stimulant treatment — reductions in injury, motor vehicle accidents, substance use disorder, criminal conviction, and educational underachievement — see Stimulant Medications and Protection, Untreated ADHD: Adverse Outcomes, and ADHD and Life Expectancy.

What's Coming: The Pipeline, Late 2025-2027

Centanafadine (Otsuka)

The single most important pipeline entry is centanafadine, a serotonin-norepinephrine-dopamine triple reuptake inhibitor (NDSRI) developed by Otsuka. Otsuka submitted the NDA on November 25, 2025. The FDA accepted the application and granted priority review in January 2026, with a PDUFA target action date of July 24, 2026.

The phase 3 program included four pivotal trials: one in children, one in adolescents, and two in adults, supporting an unusually broad single submission spanning ages 4 to 55. Across studies, centanafadine demonstrated statistically significant and clinically meaningful improvements in ADHD symptom scores (ADHD-RS-5 in pediatric and adolescent trials; AISRS in adult trials) compared with placebo. Adverse events were reported as generally mild, with decreased appetite, nausea, fatigue, abdominal pain, and somnolence in pediatric trials, and decreased appetite and headache in adult trials.

If approved, centanafadine would become the first non-stimulant ADHD medication with direct dopaminergic activity. This is mechanistically meaningful: existing non-stimulants (atomoxetine, viloxazine, alpha-2 agonists) work primarily through norepinephrine systems. Stimulant efficacy is thought to derive substantially from dopamine signaling enhancement in striatal and prefrontal circuits. A non-controlled non-stimulant that touches the dopamine system directly could occupy a clinically valuable middle space — between traditional stimulants (high efficacy, controlled status, abuse liability) and traditional non-stimulants (lower efficacy, no controlled status, no abuse liability).

Whether centanafadine actually delivers stimulant-class effect sizes without stimulant-class abuse liability is the open empirical question. The phase 3 effect sizes appear to be in the small-to-moderate range — closer to atomoxetine and viloxazine than to methylphenidate or amphetamine — though direct head-to-head comparisons have not been conducted.

Solriamfetol

Solriamfetol (Sunosi) is a dopamine-norepinephrine reuptake inhibitor currently approved for excessive daytime sleepiness in narcolepsy and obstructive sleep apnea. It has been investigated for ADHD in phase 2 trials, with mixed and modest results. It is not currently under FDA review for ADHD, though investigator-initiated work continues.

Additional Lisdexamfetamine and Methylphenidate Generics

The lisdexamfetamine generic landscape is still developing. Additional manufacturers continue to enter the market, with further price compression expected. Generic formulations of older branded methylphenidate products (Concerta, Focalin XR, Daytrana patch) have been generic for some years; the long-acting amphetamine generic landscape is less complete, with Mydayis and Adhansia XR still under brand exclusivity.

Reformulation Pipeline

The reformulation pipeline continues. Several manufacturers have indicated active programs for novel extended-release vehicles, transdermal systems beyond the existing Daytrana methylphenidate patch, and combination products. None of these is expected to fundamentally alter the prescribing landscape; they will continue to provide delivery flexibility within established molecular classes.

A Practical Clinician's Framework

Bringing this together, here is the prescribing framework I use when deciding among new and established options:

Step 1 — Pharmacological class. The first decision is stimulant versus non-stimulant. This is driven by the patient's clinical picture, comorbidity, substance use risk, cardiovascular profile, prior treatment history, and patient/family preference. Stimulants are first-line in the absence of a clear reason to avoid them.

Step 2 — Within stimulants, methylphenidate versus amphetamine. Both classes have similar effect sizes at the population level. Individual patient responses vary substantially. There is no reliable predictor of which class a given patient will respond to better. Practical considerations: amphetamine has a slightly higher abuse-liability profile and slightly longer historical track record in adult ADHD; methylphenidate has the larger pediatric evidence base. Within methylphenidate, the dexmethylphenidate (d-MPH) and racemic methylphenidate (d,l-MPH) preparations have similar effects in most patients.

Step 3 — Within class, formulation choice. This is where the post-2020 reformulation landscape matters. Once class is chosen, the prescriber matches duration, onset profile, dose flexibility, and route of administration to patient circumstances. Jornay PM for morning-functioning problems; long-duration extended-release products (Mydayis, Adhansia XR) for adolescents and adults with evening obligations; liquid and chewable products for pill-averse children; once-daily products for adherence in patients with executive-function-driven dose-timing problems.

Step 4 — Cost. Among options that fit the clinical profile, cost is decisive. Generic methylphenidate ER and generic mixed amphetamine salts are inexpensive. Generic lisdexamfetamine is now available and substantially cheaper than branded Vyvanse. Branded reformulations require a specific clinical justification beyond preference.

Step 5 — Non-stimulant selection, if needed. If a non-stimulant is being chosen first, or added to a stimulant: atomoxetine generic is the cost-rational starting choice for the SNRI-like mechanism. Qelbree is the alternative with potentially faster onset and a different side-effect profile. Guanfacine ER generic is the alpha-2 agonist of choice for daytime cognitive effects; clonidine ER generic for sleep-prominent or impulsivity-prominent presentations. Onyda XR fills the pediatric pill-averse niche.

The decision-making throughout is the same general clinical structure described in the complete ADHD guide and the medication guide. The point of this review is not to displace that structure, but to update it with the current pharmacopeia. For comprehensive side-effect framing, see ADHD Medication Side Effects. For the long-running question of medication "stopping working," see ADHD Medication Tolerance: What's Actually Happening. For pregnancy considerations, see ADHD Medications in Pregnancy and Postpartum. For parents who have ADHD themselves, see Parenting with ADHD.

What This Review Does Not Replace

This article is educational and is not medication advice for any individual patient. The medications discussed are prescription products dispensed under FDA-approved labeling that should be consulted in full for any individual prescribing decision. For individualized ADHD evaluation, see ADHD Psychiatrist NYC.

Frequently Asked Questions

Is Qelbree better than Strattera (atomoxetine)?

Not categorically. Both are non-stimulants with related but distinct mechanisms — atomoxetine is a selective norepinephrine reuptake inhibitor; viloxazine inhibits norepinephrine reuptake and additionally engages serotonergic 5-HT2C and 5-HT2B receptors. No head-to-head trial has established superiority. Effect sizes are in similar moderate ranges. Qelbree may separate from placebo somewhat earlier (within week 1 in some pediatric trials), whereas atomoxetine typically requires 2-6 weeks. Atomoxetine is generic and substantially cheaper. The choice is driven by cost, tolerability, prior trials, and insurance coverage — not by a clear efficacy difference.

Why is Azstarys Schedule II if serdexmethylphenidate is a prodrug?

Azstarys contains both serdexmethylphenidate (the prodrug, Schedule IV) and immediate-release dexmethylphenidate (Schedule II). The co-formulated branded product is dispensed at the higher schedule because of the immediate-release component. The prodrug component on its own has reduced abuse potential, but the combined product is treated like other stimulants for prescribing purposes.

Should kids start with Onyda XR or Intuniv (guanfacine ER)?

For most pill-tolerant children, generic guanfacine ER is the cost-rational first-line alpha-2 agonist. Onyda XR's niche is pediatric patients who cannot or will not swallow tablets, and patients for whom evening dosing is preferred. Generic clonidine ER tablets (Kapvay) are far cheaper than branded Onyda XR for any child who can swallow them.

Are the new ADHD medications covered by insurance?

Coverage varies. Most commercial plans require step therapy through generics first — typically generic stimulants and, for non-stimulants, generic atomoxetine before Qelbree; generic clonidine ER before Onyda XR. Manufacturer copay cards and patient assistance programs are routinely used. Prior authorization is the rule. Medicaid coverage of branded reformulations is more restrictive than commercial coverage.

What if my child cannot swallow pills?

Options have expanded substantially: Dyanavel XR (amphetamine suspension and chewable), Quillivant XR (methylphenidate suspension), Adzenys XR-ODT (amphetamine ODT), Cotempla XR-ODT (methylphenidate ODT), Quillichew ER (methylphenidate chewable), Methylin oral solution, Onyda XR (clonidine ER suspension). Many capsules can be opened and sprinkled. Pediatric behavioral programs reliably train pill-swallowing within a few sessions.

Is there anything truly new in the ADHD pipeline?

Centanafadine — a serotonin-norepinephrine-dopamine triple reuptake inhibitor developed by Otsuka — is under FDA priority review with a target action date of July 24, 2026. If approved, it would be the first non-stimulant with direct dopaminergic activity, occupying a mechanistic middle space between stimulants and existing non-stimulants. Beyond centanafadine, the pipeline is dominated by additional reformulations rather than new molecular entities.

Primary References

Further Reading

• ADHD Pharmacology and the Natural Course of Illness — companion review of the underlying drug classes and how treatment intersects with the natural course of ADHD across the lifespan
• Untreated ADHD: Adverse Outcomes — the population-level evidence for why pharmacological treatment matters
• ADHD Medication Guide — comprehensive reference on all currently used ADHD medications
• ADHD Medication Side Effects — what to expect, what to watch for, and how to manage common adverse effects
• ADHD Drug Holidays — when they help, when they don't, and what the growth-recovery data show
• Concerta vs. Ritalin — the most commonly confused methylphenidate products, compared in detail
• Adderall vs. Vyvanse — the two most widely prescribed amphetamine-class products, including the post-generic landscape
• Wellbutrin (Bupropion) for ADHD — the off-label option that comes up in every non-stimulant conversation
• Stimulants vs. Non-Stimulants — the foundational class-comparison framework
• Choosing Between Stimulants and Non-Stimulants — patient-facing decision framework
• Stimulant Medications and Protection from Adverse Outcomes — the protective-effects evidence base
• ADHD Medications and Cardiovascular Safety — what the large-scale evidence actually shows
• ADHD Medication Tolerance — when medications appear to "stop working" and what is actually happening
• ADHD and Life Expectancy — the UK matched cohort, Barkley data, and treatment implications
• ADHD in Pregnancy and Postpartum — medication decisions during reproductive transitions
• Parenting with ADHD — the parent who recognizes themselves in the child's evaluation
• ADHD Psychiatrist NYC — evaluation and medication management for adults and adolescents with ADHD